Fall 2025
Posted on 9/5/2024
AI-driven drug discovery for pharmaceuticals
No salary listed
Burlingame, CA, USA
Hybrid
Genesis Therapeutics focuses on developing new medicines by using artificial intelligence in the drug discovery process. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach allows Genesis Therapeutics to explore new chemical spaces and discover novel protein targets, which can lead to important new medicines. The company primarily serves other biotech and pharmaceutical firms, exemplified by its partnership with Eli Lilly, which includes a significant financial deal. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, generating revenue through strategic partnerships and upfront payments, as well as potential future earnings based on the success of the drugs developed. The goal of Genesis Therapeutics is to accelerate the drug discovery process and bring new treatments to market more efficiently.
Company Size
51-200
Company Stage
Series B
Total Funding
$280.1M
Headquarters
Burlingame, California
Founded
2019
Help us improve and share your feedback! Did you find this helpful?
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program
Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.
Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.
Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.
Genesis Therapeutics receives equity investment from NVIDIA.
Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.